BR112021017365A2 - Receptores de citocina quiméricos constitutivamente ativos - Google Patents
Receptores de citocina quiméricos constitutivamente ativosInfo
- Publication number
- BR112021017365A2 BR112021017365A2 BR112021017365A BR112021017365A BR112021017365A2 BR 112021017365 A2 BR112021017365 A2 BR 112021017365A2 BR 112021017365 A BR112021017365 A BR 112021017365A BR 112021017365 A BR112021017365 A BR 112021017365A BR 112021017365 A2 BR112021017365 A2 BR 112021017365A2
- Authority
- BR
- Brazil
- Prior art keywords
- constitutively active
- cytokine receptors
- chimeric cytokine
- active chimeric
- caccrs
- Prior art date
Links
- 102000003675 cytokine receptors Human genes 0.000 title abstract 3
- 108010057085 cytokine receptors Proteins 0.000 title abstract 3
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000002688 persistence Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4635—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
Abstract
receptores de citocina quiméricos constitutivamente ativos. trata-se de receptores de citocinas quiméricos constitutivamente ativos (caccrs). quando presentes em células imunológicas portadoras de receptor de antígeno quimérico (car), tais caccrs permitem maior ativação, proliferação, persistência e/ou potência de células imunológicas. também são fornecidos métodos para se produzir e usar os caccrs aqui descritos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962812911P | 2019-03-01 | 2019-03-01 | |
US202062980823P | 2020-02-24 | 2020-02-24 | |
PCT/US2020/020415 WO2020180694A1 (en) | 2019-03-01 | 2020-02-28 | Constitutively active chimeric cytokine receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021017365A2 true BR112021017365A2 (pt) | 2022-02-01 |
Family
ID=70057286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021017365A BR112021017365A2 (pt) | 2019-03-01 | 2020-02-28 | Receptores de citocina quiméricos constitutivamente ativos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200291090A1 (pt) |
EP (1) | EP3931207A1 (pt) |
JP (1) | JP2022522786A (pt) |
KR (1) | KR20210136041A (pt) |
CN (1) | CN113508128A (pt) |
AU (1) | AU2020232597A1 (pt) |
BR (1) | BR112021017365A2 (pt) |
CA (1) | CA3129865A1 (pt) |
CO (1) | CO2021011198A2 (pt) |
IL (1) | IL285939A (pt) |
MX (1) | MX2021010443A (pt) |
PE (1) | PE20211902A1 (pt) |
SG (1) | SG11202107984RA (pt) |
WO (1) | WO2020180694A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021010444A (es) | 2019-03-01 | 2021-09-21 | Allogene Therapeutics Inc | Receptores de citocinas quimericos que tienen un ectodominio de pd-1. |
BR112022016657A2 (pt) * | 2020-02-24 | 2022-12-20 | Allogene Therapeutics Inc | Células car-t bcma com atividades melhoradas |
AU2021312871A1 (en) | 2020-07-21 | 2023-02-09 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
WO2022222905A1 (en) * | 2021-04-19 | 2022-10-27 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and uses thereof in cellular therapies |
US20230346934A1 (en) | 2022-03-29 | 2023-11-02 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
WO2007075899A2 (en) * | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
US8841074B2 (en) * | 2009-12-04 | 2014-09-23 | Quest Diagnostics Investments Incorporated | MPL mutations in JAK2 V617F negative patients with myeloproliferative disease |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
US11014989B2 (en) | 2015-01-26 | 2021-05-25 | Cellectis | Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy |
BR112017019914A2 (pt) | 2015-04-13 | 2018-06-19 | Pfizer | receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b |
US20180318303A1 (en) * | 2015-04-15 | 2018-11-08 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
CA3034873A1 (en) * | 2016-08-26 | 2018-03-01 | Baylor College Of Medicine | Constitutively active cytokine receptors for cell therapy |
GB201702617D0 (en) * | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
MX2020009051A (es) * | 2018-03-02 | 2020-12-03 | Allogene Therapeutics Inc | Receptores de citocina quimericos inducibles. |
-
2020
- 2020-02-28 PE PE2021001432A patent/PE20211902A1/es unknown
- 2020-02-28 WO PCT/US2020/020415 patent/WO2020180694A1/en active Application Filing
- 2020-02-28 JP JP2021551799A patent/JP2022522786A/ja active Pending
- 2020-02-28 CN CN202080018237.6A patent/CN113508128A/zh active Pending
- 2020-02-28 CA CA3129865A patent/CA3129865A1/en active Pending
- 2020-02-28 KR KR1020217030491A patent/KR20210136041A/ko unknown
- 2020-02-28 US US16/804,917 patent/US20200291090A1/en active Pending
- 2020-02-28 SG SG11202107984RA patent/SG11202107984RA/en unknown
- 2020-02-28 BR BR112021017365A patent/BR112021017365A2/pt unknown
- 2020-02-28 EP EP20715579.7A patent/EP3931207A1/en active Pending
- 2020-02-28 MX MX2021010443A patent/MX2021010443A/es unknown
- 2020-02-28 AU AU2020232597A patent/AU2020232597A1/en active Pending
-
2021
- 2021-08-25 CO CONC2021/0011198A patent/CO2021011198A2/es unknown
- 2021-08-29 IL IL285939A patent/IL285939A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210136041A (ko) | 2021-11-16 |
PE20211902A1 (es) | 2021-09-27 |
IL285939A (en) | 2021-10-31 |
EP3931207A1 (en) | 2022-01-05 |
CO2021011198A2 (es) | 2021-09-09 |
MX2021010443A (es) | 2021-12-10 |
CA3129865A1 (en) | 2020-09-10 |
AU2020232597A1 (en) | 2021-08-19 |
CN113508128A (zh) | 2021-10-15 |
WO2020180694A1 (en) | 2020-09-10 |
US20200291090A1 (en) | 2020-09-17 |
SG11202107984RA (en) | 2021-08-30 |
JP2022522786A (ja) | 2022-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021017365A2 (pt) | Receptores de citocina quiméricos constitutivamente ativos | |
ZA202007393B (en) | Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy | |
AU2018338647A1 (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
WO2019147805A3 (en) | Regulatory t cells targeted with chimeric antigen receptors | |
BR112021017113A2 (pt) | Receptores de citocinas quiméricos portadores de um ectodomínio de pd-1 | |
MX2020010241A (es) | Composiciones de inmunoterapia celular y usos de las mismas. | |
WO2020092854A3 (en) | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) | |
PH12019502411A1 (en) | Cells expressing chimeric activitaing receptors and chimeric stimulating receptors and uses thereof | |
EA201992469A1 (ru) | Антигенспецифические иммунные эффекторные клетки | |
CR20200014A (es) | Molécula de polipéptido con especificidad dual mejorada | |
EA201790624A1 (ru) | Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии | |
BR112022016657A2 (pt) | Células car-t bcma com atividades melhoradas | |
PH12020500677A1 (en) | Neoantigens and uses thereof | |
BR112021021843A2 (pt) | Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas | |
MX2019012360A (es) | Composiciones y metodos mejorados de celulas t. | |
PE20170908A1 (es) | VARIANTES DE INTERFERON a2b | |
MX2021002190A (es) | Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20. | |
MX2019001651A (es) | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. | |
WO2004029092A8 (fr) | Anticorps pour adcc et induisant la production de cytokines. | |
BR112022003553A2 (pt) | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta | |
EA202091982A1 (ru) | Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии | |
WO2019232409A9 (en) | Methods for genome editing and activation of cells | |
WO2019242632A8 (en) | Engineered cells and uses thereof | |
MX2021005485A (es) | Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo. | |
BR112021016435A2 (pt) | Receptores de antígenos quiméricos responsivos à hipóxia |